1. CGRP Antibodies in Migraine

2. This program will include a discussion of off-label and investigational agents not approved by the FDA for use in the US and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. 1970s to 1990s: Era of Characterizing Innervation and Neural Regulation of Cerebral Blood Vessels

4. Demonstration of Perivascular CGRP Nerves and Potent Vasodilation by CGRP in Cerebral Arteries

5. The Trigeminovascular Reflex

6. Triptans Suppress CGRP Release From Trigeminal Nerves Via Presynaptic 5-HT1B/D Receptors

7. CGRP-Targeting Therapy for Prevention and Acute Treatment of Migraine

8. Pharmacologic Characteristics of CGRP-Targeting mAbs

9. CGRP-Targeting mAbs for Migraine Prevention

10. CGRP-Targeting Small Molecules for the Treatment of Migraine

11. CGRP-Targeting mAbs: 50% Responder Rates in Phase 3 Studies of EM

12. CGRP-Targeting mAbs: 75% Responder Rates in Phase 3 Studies of EM

13. Considerations for Clinical Practice: Dosing and Onset of Action

14. Considerations for Clinical Practice: Adverse Events

15. Considerations for Clinical Practice: Patient and Treatment Factors

16. Conclusions

17. Abbreviations

18. Abbreviations (cont)